Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Earnings for Agile Therapeutics, Inc. (AGRX)
Earnings in 2023 (TTM): $-14,465,000
According to Agile Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-14,465,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Agile Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-14,465,000 | $-14,465,000 |
| 2022 | $-30,087,000 | $-25,412,000 |
| 2021 | $-74,894,000 | $-76,585,000 |
| 2020 | $-51,853,000 | $-54,686,000 |
| 2019 | $-18,606,000 | $-18,443,000 |
| 2018 | $-20,256,000 | $-19,779,000 |
| 2017 | $-28,304,000 | $-28,304,000 |
| 2016 | $-31,816,000 | $-28,741,000 |
| 2015 | $-36,307,000 | $-30,335,000 |
| 2014 | $-19,730,000 | $-16,077,000 |
| 2013 | $-14,320,620 | $-14,320,620 |
| 2012 | $-23,260,127 | $-23,260,127 |